Biomed Lublin, PLBMDLB00018

Synthaverse pursues debt refinancing: what it means for Synthaverse stock

Published on 10/13/2026 at 05:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Synthaverse reported PLN 26.46 million in first-half revenue, up 34.23 percent year over year. The next report on December 2, 2026 gives Synthaverse stock a dated checkpoint.

Key points in brief

  • Synthaverse is pursuing debt optimization and refinancing after its first-half 2026 report.
  • Revenue reached PLN 26.46 million in the first half of 2026, up 34.23 percent year over year.
  • EBITDA rose to PLN 5.42 million, while net income remained negative at PLN 6.37 million.
  • The next reporting date is December 2, 2026, according to Investing.com.
Biomed Lublin, PLBMDLB00018, Illustration mit AI erstellt.
Biomed Lublin, PLBMDLB00018, Illustration mit AI erstellt.

Synthaverse is pursuing debt optimization and refinancing after reporting PLN 26.46 million in revenue for the first half of 2026, up 34.23 percent year over year. BiznesRadar reported on September 30, 2026 that the company was also working to optimize and refinance its debt.

What does refinancing mean for debt?

Stockd reported that total debt stood at PLN 83.26 million at the end of the first half of 2026, while cash was PLN 0.35 million. That balance makes financing costs a central test for the operating recovery.

The same analysis showed EBITDA of PLN 5.42 million and an EBITDA margin of 20.46 percent for the first half of 2026. Net income was still negative at PLN 6.37 million, so stronger sales have not yet produced a positive bottom line.

Three dated operating milestones

On June 29, 2026, a shareholder notification recorded a 15.69 percent stake for Investcare, according to Stockd. The figure marked a change in the company's disclosed ownership structure.

The reporting period ended on June 30, 2026, with revenue of PLN 26.46 million and operating profit of minus PLN 1.34 million, according to BiznesRadar. The half-year report was published on September 30, 2026, and the refinancing process was identified as a parallel priority on October 2, 2026 by Przemysl Farmaceutyczny.

Next report date is December 2

Investing.com lists December 2, 2026 as Synthaverse's next reporting date. That event should provide the next dated test of revenue growth, financing costs and the company's ability to convert operating progress into net income.

Warsaw quote stays below yearly high

Synthaverse was last at PLN 2.81 on the Warsaw Stock Exchange on October 12, 2026 at 4:59 p.m. CEST. Its market capitalization was PLN 214.0 million, with a 52-week range of PLN 2.60 to PLN 4.34 on the same date. The stock therefore remained 35.25 percent below its 52-week high, calculated from the same-currency quote and range.

The further course of trading is shown by the continuously updated real-time quote of Synthaverse stock.

Synthaverse stock facts

  • Company: Synthaverse S.A.
  • ISIN: PLBMDLB00018
  • Ticker: SVE
  • Primary exchange: GPW Warsaw Stock Exchange
  • Last price: PLN 2.81 on October 12, 2026 at 4:59 p.m. CEST
  • Market capitalization: PLN 214.0 million as of October 12, 2026
  • 52-week range: PLN 2.60-PLN 4.34 as of October 12, 2026
  • Sector / Industry: Healthcare / Biotechnology
  • Next earnings date: December 2, 2026

Market context: Market report WIG 20.

More news and analyses on Synthaverse stock

Disclaimer...

en | PLBMDLB00018 | BIOMED LUBLIN | boerse | 70308413 | bgmi